Urokinase-activated human plasma was analysed by acetic acid/urea/polyacrylamide-gel electrophoresis. The bands representing plasminogen, the plasmin--x2-plasmin inhibitor and plasmin-xa2-macroglobulin complexes were identified by immunoprecipitation with specific antibodies and by comparison with purified components. Plasminogen and the plasmin-inhibitor complexes were isolated from plasma or thrombin-clotted plasma containing 1251.-labelled Glu-plasminogen (residues 1-790) and urokinase. The plasma was kept at 37°C for 0.5 and 10 times the lysis time of the clotted plasma, the clotted plasma until lysis. The plasmin heavy chain from the plasmin-inhibitor complexes was subsequently prepared. Only in one case could a low-grade proteolytic conversion of Glu-forms into Lys/Met/Val-forms (residues 77-790, 68-790 and 78-790 respectively) during the preparations be detected. Sodium dodecyl sulphate/polyacrylamide-gel electrophoresis and Nterminal sequence analysis of the purified plasminogen and plasmin heavy chain showed the following. The plasminogen in plasma was on the Glu-form. Glu-plasmin constituted 0.74 and 0.58 of the plasmin bound to the C2-plasmin inhibitor in plasma after brief and prolonged activation respectively. The rest was Lys/Met/Val-plasmin. The clotted plasma contained about equal amounts of Glu-plasminogen and Lys/Met/Val-plasminogen, and predominantly Lys/Met/Val-plasmin complexed to a2-plasmin inhibitor and x2-macroglobulin. The results of the analysis of the purified material substantiated the identity of radioactive protein bands in the gel after acetic acid/urea/polyacrylamide-gel electrophoresis.
cular the identity of compounds with different mobilities in acetic acid/urea/polyacrylamide-gel electrophoresis, in order to use this analytical tool for a quantitative determination of the compounds as a function of time in a subsequent study (Thorsen et al., 1984) .
Experimental Materials
Buffers and chemicals. Tris buffer (I0.15), pH7.70 (20°C) , and gelatin Tris buffer (I0.15), pH17.70 (20°C), have been described previously (Thorsen, 1975) .
Dithioerythritol, p-nitrophenyl p'-guanidinobenzoate and sodium iodoacetate were from Sigma Chemical Co., St. Louis, MO, U.S.A. p-Nitrophenyl p'-guanidinobenzoate was dissolved as described by Kezdy & Kaiser (1970) . Ammonium heparinate (146i.u./mg) was from Leo Pharmaceuticals, Ballerup, Denmark.
Proteins. Aprotinin (Trasylol) (courtesy of Dr. Philipp, Bayer, Leverkusen, Germany), bovine thrombin (96 NIH units/mg) and human urokinase (EC 3.4.21.31 , 7700 Ploug units/mg) have been described previously (Thorsen, 1975) . SDS/polyacrylamide-gel electrophoresis followed by zymographic analysis (Granelli-Piperno & Reich, 1978) demonstrated the two forms of urokinase with M, 31000 and 54000. Glu-plasminogen, aprotinin-inhibited Glu-plasmin, Lys-plasminogen, aprotinininhibited Lys-plasmin and the plasminogenbinding form of a2-plasmin inhibitor were prepared as described previously Suenson & Thorsen, 1981; Thorsen et al., 1981) .
Human plasma. This was prepared from citrated out-dated human donor blood. Plasma was centrifuged at 23 OOOg at 4°C for 2 h, and the clear plasma was siphoned off.
Antibodies against humanproteins. Specific rabbit immunoglobulins against plasma inhibitors, plasminogen and urokinase were those previously reported (Mullertz, 1974; Clemmensen & Christensen, 1976; Clemmensen et al., 1981) .
Methods
Determination ofthe concentration ofprotein. The concentration of purified plasminogen forms was calculated from the absorbance at 280nm (Thorsen & Mullertz, 1974) of purified a2-plasmin inhibitor by active-site titration (Mullertz & Clemmensen, 1976) of Glu-plasminogen or inhibitors in plasma by electroimmunoassay (Laurell, 1972) , with purified Glu-plasminogen, purified (x2-plasmin inhibitor or a2-macroglobulin in Protein-StandardPlasma (Behringwerke, Marburg, Germany) being used for calibration.
Labelling ofplasminogen with 125L. This was performed as previously described . The specific radioactivity ranged between 1 and 11 mCi/pmol of plasminogen. The incorporation of iodine into plasminogen was less than 1 gatom/mol.
Polyacrylamide-gel electrophoresis in the presence of SDS and of acetic acid/urea. These were performed as described previously (Suenson & Thorsen, 1981) , except that gels for electrophoresis in the presence of acetic acid/urea contained an upper layer (length around 1Omm) with acrylamide (48.7 g/1) and NN'-methylenebisacrylamide (1.3g/1). This allowed high-molecular-mass proteins to penetrate into the gel.
Autoradiography and quantification of 125JI labelled plasminogen derivatives by polyacrylamidegel electrophoresis. Both were performed as described previously (Suenson & Thorsen, 1981 Table 1 was calculated from the coefficients of variation (V) (Vy,,2 = V2 +V2), and differences were evaluated by Student's t test.
The conversion of labelled Glu-plasminogen into Lys-plasminogen did not result in any loss of radioactivity (n = 4, P > 0.1; Student's t test), when estimated as described above by acetic acid/urea/polyacrylamide-gel electrophoresis of samples containing Glu-plasminogen and of Lysplasminogen prepared from Glu-plasminogen by treatment with trace amounts of urokinase (Thorsen & Mullertz, 1974) . The radioactivity of the light chain as a fraction of the radioactivity of the heavy chain+light chain of aprotinin-inhibited Glu-plasmin [mean + S.D. (n)] was 0.41+0.015 (6).
The total radioactivity in the gel track was more than 94% of that of the sample applied.
Preparation of '25I-labelled plasmin-ca2-plasmin inhibitor complexfrom purified components. Labelled plasminogen was activated by urokinase at a molar excess of Ox2-plasmin inhibitor (Wiman & Collen, 1979) . The mixture in Tris buffer contained plasminogen (7 gM), a2-plasmin inhibitor (11-13.unM), and urokinase (8 x 105 Ploug units/i). It was incubated for 30min (Lys-plasminogen) or 60min (Glu-plasminogen) at 37°C, and the reaction was quenched by addition of 2vol. of acetic acid (1.75M)/urea (9M). It was stored at 4°C and used within 2h. Plasmin heavy chains from complexes prepared from Glu-plasminogen and Lys-plasminogen had M, 65000 and 60000 respectively, indicating that the N-terminal peptide fragments were not released from Glu-plasminogen at an excess of a2-plasmin inhibitor (Wiman & Collen, 1979) .
Identification by immunoprecipitation of a2-plasmin inhibitor and aC2-macroglobulin complexed to I 25I-labelled plasmin. Plasma without Factor XIII with added I 2II-labelled Glu-plasminogen was mixed with urokinase in gelatin/Tris buffer, or with a mixture of urokinase and thrombin as described (Thorsen et al., 1984) , and incubated at 37°C. After a given time (after lysis of fibrin in clotted plasma) aprotinin was added to 17 pm, ammonium heparinate (plasma only) to 36 units/I, and specific rabbit immunoglobulins against aC2-plasmin inhibitor (3 vol.) or against a2-macroglobulin (1 vol.). After incubation for 30min at 37°C and 18 h at 4°C, the immunoprecipitates were collected by centrifugation, washed in NaCl (1 50mM) at 4°C and resuspended in acetic acid (1.25M)/urea (6M). The plasma samples (before and after immunoprecipitation) diluted in 2vol. of acetic acid (1.75M)/urea (9M), and the solubilized immunoprecipitates were subjected to acetic acid/urea/polyacrylamide-gel electrophoresis followed by autoradiography. The supernatants after immunoprecipitation did not contain inhibitor-antigenic material when tested by electroimmunoassay.
Isolation of plasminogen and plasmin-inhibitor complexes from urokinase-activated plasma and clotted plasma. To plasma was added I 25I-labelled Glu-plasminogen and urokinase. One specimen was coagulated by thrombin (103 NIH units/i) (CP) and kept at 37°C until lysis (about 1.4ks). Two specimens were kept as plasma at 370C, one for 0.5 lysis times (P1) and the other for 10 lysis times (P2) of that of CP. The final concentration of urokinase was 25 x 103-40 x 103 Ploug units/l, adjusted to yield a lysis time about 1.4ks of thrombin-coagulated aliquots. The ratio of radiolabelled plasminogen to total plasminogen was 0.03 (P1 and CP) and 0.001 (P2). The volumes of plasma (undiluted) processed were 833ml (P1), 1618ml (P2), and 810ml (CP). The activation was stopped by addition of specific rabbit immunoglobulin against urokinase, in amounts found to prevent the lysis of clotted samples of plasma (1 ml per 5000 Ploug units). Then the material was diluted with 2 vol. of ice-cold sodium phosphate buffer (100mM), pH7.4, containing aprotinin (5pM) and p-nitrophenyl p'-guanidinobenzoate (10 jiM). The diluted material (P1 and CP) was divided into nine 350 ml portions, quickly frozen in a bath of solid-C02/acetone, and stored at -20°C. Three portions were processed simultaneously at 4°C. Each portion was applied to a column (Pharmacia K 26/40) containing 60ml of lysine-Sepharose 4B equilibrated with sodium phosphate buffer (100mm), pH 7.4, containing aprotinin (5 uM) and p-nitrophenyl p'-guanidinobenzoate (1O gM). The gel was washed with the equilibration buffer until A1 cm,280 was less than 0.02. The I25I-labelled material was eluted with the same buffer, but containing 6-aminohexanoic acid (20mM). The eluted fractions were collected in 0.2 vol. of acetic acid (1OM) to give a final pH of 3.4. The radioactive fractions from the three columns were pooled and concentrated to a volume of about 30ml and subjected to gel filtration on a column (Pharmacia K 50/100) containing 1700ml of Ultrogel AcA-34 (LKB, Stockholm, Sweden) and equilibrated and eluted with glycine (50mM)/HCl (50mM)/NaCl (300mM), pH3.4, or with acetic acid (2.5M)/sodium acetate (100mM)/NaCl (200mM), pH3.4. The radioactivity and the protein (measured by A280) were eluted in a minor and two major peaks that contained the plasmin-ix2-macroglobulin complex, the plasmin-xa2-plasmin inhibitor complex and the plasminogen respectively. Fractions of the central parts of the peaks were pooled and concentrated by ultrafiltration to Alcm, 280 -= (plasmininhibitor complexes) or to A1 cm,280 = 2.5 (plasminogen). The buffer of the plasminogen pool was exchanged with acetic acid (0.5M) by Sephadex G-25 gel filtration, concentrated and freeze-dried. The pools of the plasmin-inhibitor complexes were stored at -20°C. The lysine-Sepharose step of P2 was done as follows. Plasma (2 litres) was stirred with lysineSepharose (600ml) for 1 h at 4°C and washed on a Buchner funnel with phosphate buffer (100mM), pH7.4. The gel was packed in a column (Pharmacia K 50/60) and eluted with the same buffer (1800ml) containing a linear gradient of 6-aminohexanoic acid from 0 to 20mM.
Determination of the amount ofsubstance ofplasminogen derivatives in the plasma samples and in the purified materials of the preparative experiments.
The concentration of plasminogen in the purified plasminogen preparation and the radioactivity determined and the molar radioactivity were calculated. The total amount of substance of plasminogen derivatives in any material was calculated by dividing the total radioactivity of the material by the molar radioactivity of plasminogen. The
Vol. 223 amount of substance of each component was then calculated from the distribution of the radioactivity in the gel after electrophoresis as described above. This was possible because the molar radioactivity of the various forms of plasminogen and plasmin did not differ.
Preparation of the plasmin heavy chain from the plasmin-inhibitor complexes. This was done as described by Wiman & Collen (1979) , after adjustment of the pH of the acid pools with Tris base to 8.4. The solutions were desalted by Sephadex G-25 gel filtration in acetic acid (0.5M), concentrated by ultrafiltration and freeze-dried.
Amino acid sequence determination. Samples (2-lOnmol) were subjected to manual Edman degradation similar to the procedure described by Skorstensgard et al. (1982) , or to automated Edman degradation in a Beckman 890 C instrument as in Sottrup-Jensen et al. (1981) . Phenylthiohydantoin derivatives of amino acids were analysed by highperformance liquid chromatography on columns of Spherisorb 5 S (octadecylsilane-coated) as described by Sottrup-Jensen et al. (1980) .
Results and discussion Electrophoretic mobility of plasminogen derivatives and identification ofplasmin-inhibitor complexes in plasma Acetic acid/urea/polyacrylamide-gel electrophoresis of urokinase-activated plasma and clotted plasma with 125I-labelled Glu-plasminogen displayed four radioactive zones in the gel. From the cathode towards the anode they were as follows: zones 1 and 2 represented plasminogen, zone 3 represented the plasmin-ca2-plasmin inhibitor complex and zone 4, close to the site of application, represented the plasmin-a2-macroglobulin complex (Fig. 1, track a) . The evidence is as follows.
Zone 1 was a double band migrating as Lys-plasminogen (cathodic plasminogen) (Fig. 1, tracks a and c). Zone 2 was a double band migrating as Gluplasminogen (anodic plasminogen) (Fig. 1 , tracks a and c). The double bands represented the two carbohydrate variants of the proenzyme (Walther et al., 1975) .
Zone 3 displayed three bands. Two of the bands 
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were observed in plasma and in activated clotted plasma at the time of clot lysis (Fig. 1, tracks b, d, e and J). They had the same relative mobilities (anodic and cathodic) as purified complexes of the a2-plasmin inhibitor assumed to contain Glu-plasmin and Lys-plasmin respectively (Fig. 1 , tracks g and h). Activated clotted plasma incubated 6 times its lysis time displayed the cathodic band described above (Fig. 1, track a) and in addition another band that migrated somewhat further towards the cathode. The latter band increased with the time after clot lysis (Thorsen et al., 1984) . All bands of zone 3 were removed by immunoprecipitation with specific rabbit immunoglobulin against a2-plasmin inhibitor and were recovered in the immunoprecipitate (Fig. 2) . Zone 4 was removed by immunoprecipitation with specific rabbit immunoglobulin against a2-macroglobulin and was recovered in the immunoprecipitate (Fig. 2) . The mobility and the pattern of the bands of zone 3 depended on the length of preincubation of the sample in acetic acid/urea. After a short preincubation (< 10 min at 5°C) the bands migrated as shown in Figs. 1 and 2 . After a long preincubation (>24 h at 5°C) the total zone had a moreanodic mobility, and only two bands, an anodic and a cathodic band, were seen, the former corresponding to the anodic band, the latter to the cathodic bands, observed after a short preincubation (Fig. 3) . The 'short incubation pattem' was often difficult to reproduce with purified material.
Purification of the plasminogen and the plasmininhibitor complexes. These experiments were done without removal of Factor XIII as opposed to those of the following paper (Thorsen et al., 1984) . Plasma with added 125I-labelled Glu-plasminogen was activated with urokinase for a short period (P1) and a long period (P2) and until complete lysis of clotted plasma (CP). The distribution of the plasminogen and plasmin-inhibitor complexes after acetic acid/urea/polyacrylamide-gel electrophoresis was similar to that demonstrated in Fig. 1 (tracks e, f and b). The 125I-labelled plasminogen and the I 251-labelled plasmin-inhibitor complexes were purified from P1, P2 and CP. The pattern of the gels after acetic acid/urea/polyacrylamide-gel electrophoresis of these preparations is shown in Fig. 4 . Whereas plasminogen was very pure, the preparations of the plasmin-inhibitor complexes contained some protein impurities. Further purifi- acid/urealpolyacrylamide-gel electrophoresis of the plasmmf-ca2-plasmin inhibitor complex after a short and a long preincubation in acetic acid/urea The complex was prepared from plasma incubated for 0.5 lysis times (P1) and from clotted and lysed plasma (CP) (see the Experimental section). A sample was incubated at 5°C for 5min (A) and 24h (B) in acetic acid/urea before electrophoresis. The gel slabs were stained for protein. Abbreviations: see the legend to Fig. 1. cation was abstained from, because it increased the risk of proteolytic degradation. Furthermore, the impurities were removed by the subsequent isolation of the plasmin heavy chain. The radioactive fraction of the main component was 0.92-0.97 (plasminogen, plasmin-cz2-plasmin inhibitor complex) and 0.83 (plasmin--c2-macroglobulin complex from CP). Table 1 shows the fractional distribution and the total amount of substance of the components both in plasma and in the partially purified preparations.
The recoveries were low, in particular those of the plasmin-inhibitor complexes from the plasma experiments (P1 and P2). The major losses occurred in the gel-filtration steps. The (cathodic form)/(anodic + cathodic forms) ratios of the plasmin-ac2-plasmin inhibitor and of plasminogen derivatives in seven purified preparations Plasma or clotted plasma was activated by urokinase followed by purification of components by affinity chromatography on lysine-Sepharose 4B and gel filtration on Ultrogel AcA-34 as described in the Experimental Section. Plasmin-x2-plasmin inhibitor complex (P-a2PI), plasminogen (Pg) and plasmin-(x2-macroglobulin complex (P-a2M) were from plasma incubated 0.5 lysis times (P1) and 10 lysis times (P2) and clotted plasma incubated until complete lysis (CP). The samples were diluted with 2 vol. of acetic acid (1.75M)/urea (9M) and incubated for 24h at room temperature. (a)-(c) Preparation of P-a2PI from P1 (a), P2 (b) and CP (c); (d)-(J) preparation of Pg from P1 (d), P2 (e) and CP (f); (g) preparation of P-a2M from CP (separate experiment). (Table 1) were of interest, because an increase during the preparative procedure would indicate proteolytic (by plasmin) degradation. In one case (P1) there was a significant but small increase in the amount of degraded plasminogen. The other increases (if any) were insignificant. Identification of the molecular forms ofplasminogen Plasminogen purified from P1 and P2, which predominantly contained the anodic form (Table  1) , mainly migrated as Glu-plasminogen in acetic acid/urea/polyacrylamide-gel and SDS/polyacrylamide-gel electrophoresis (Figs. 4 and 5 ) and displayed the dominating N-terminal sequence GluPro (Table 2) . Plasminogen purified from CP, which contained about equal amounts of anodic and cathodic forms (Table 1) , migrated as Glu-and Lys-plasminogen in acetic acid/urea/polyacrylamide and SDS/polyacrylamide-gel electrophoresis (Figs. 4 and 5) and displayed the Nterminal sequence Glu-Pro (fraction= 0.4), and the sequences Met/Lys-Val/Val-Tyr (fraction = 0.6) ( Table 2 ). These sequences are characteristic for Glu-plasminogen and Lys/Met/Valplasminogen respectively (Sottrup-Jensen et al., 1978a,b) .
Hence anodic plasminogen in plasma and clotted plasma and cathodic plasminogen demonstrated in clotted plasma by acetic acid/urea/polyacrylamide-gel electrophoresis (Fig. 1) are Gluand Lys/Met/Val-plasminogen respectively.
Free Glu-plasmin and Lys/Met/Val-plasmin migrate as their analogous plasminogen forms in acid/urea/polyacrylamide-gel electrophoresis of non-reduced samples (Suenson & Thorsen, 1981) .
The amount of free plasmin in the urokinase-activated plasma and clotted plasma was small, as plasmin light chain was present in only trace amounts in reduced samples of the purified plasminogen. This is compatible with the fact that a2-
plasmin inhibitor binds plasmin rapidly and strongly (Christensen & Clemmensen, 1978; Wiman & Collen, 1978 Table 1 .
The fractions of heavy chain recovered from the complex in the preparations were 0.53 (P1), 0.43 (P2) and 0.43 (CP). The plasmin heavy chain isolated from the complex of P1, which predominantly contained the anodic form of the complex (Table 1) , displayed the dominating N-terminal sequence characteristic for Glu-plasmin (Table 2 ) (Sottrup-Jensen et al., 1978a,b) . The plasmin heavy chain isolated from the complex of CP, which predominantly contained the cathodic forms of the complex (Table 1) , displayed predominantly the Nterminal sequence characteristic for Lys/Met/Valplasmin (Table 2) (Sottrup-Jensen et al., 1978a,b) . Only an incomplete separation of the Glu-and the Lys/Met/Val-plasmin heavy chain by SDS/polyacrylamide-gel electrophoresis was achieved. However, the plasmin heavy chain of the complex prepared from P1 and CP migrated mainly as the Glu form and the Lys/Met/Val-form respectively (results not shown). After prolonged activation of plasma (P2), somewhat more of the anodic (0.58) than the cathodic form (0.42) of the complex was formed (Table 1) . About equal amounts of the Nterminal sequences (Table 2) were observed. The band 2 of the cathodic plasmin-cz2-plasmin inhibitor complex (Fig. 1 ) appeared only when most of the ac2-plasmin inhibitor was complexed to plasmin (Thorsen et al., 1984) . It was not present in Table 2 . Expected and determined N-terminal amino acid sequences of plasmin from the plasmin-inhibitor complexes and plasminogen The presumed distribution of the N-terminal sequences was calculated from the distribution of the components by acetic acid/urea/polyacrylamide-gel electrophoresis (Table 1) on the presupposition that cathodic plasminogen, and plasmin from plasmin-a2-macroglobulin and from cathodic plasmin-a2-plasmin inhibitor complex, have N-terminal Met/Val/Lys, whereas anodic plasminogen, and plasmin from anodic plasmin-a2-plasmin inhibitor, have N-terminal Glu. The fractional distribution was calculated from N-terminal sequence analysis of the plasmin heavy chain isolated from the plasmin-inhibitor complexes and from plasminogen. For abbreviations see the legend to the purified plasmin-inhibitor complex assumed to contain Lys-plasmin (see the Experimental section) (Fig. 1) . The band probably reflected a plasmin-catalysed cleavage of peptide bonds in the plasmin light chain or in the a2-plasmin inhibitor of the complex (Wiman & Collen, 1979) .
Plasma contains a plasminogen-binding and a non-plasminogen-binding form of the x2-plasmin inhibitor . These forms have identical mobilities in acid/urea/polyacrylamide-gel electrophoresis when they are complexed to Glu-or Lys-plasmin. Hence the anodic and the cathodic forms of plasmin-a2-plasmin inhibitor complex demonstrated in plasma and clotted plasma by acid/ urea/polyacrylamide-gel electrophoresis (Fig. 1) contain Glu-plasmin and Lys/Met/Val-plasmin respectively.
Identification ofplasmin heavy chain in the plasmin-
%2-macroglobulin complex
The complex was recovered from CP only in amounts sufficient for isolation of the plasmin heavy chain. The molar fraction of heavy chain recovered from the purified complex from CP was 0.34. The heavy chain migrated predominantly as Lys-plasmin heavy chain in SDS/polyacrylamidegel electrophoresis and displayed the dominating N-terminal sequence, Lys-Val, characteristic for Lys-plasmin (Table 2 ). The sequence Glu-Pro was also observed, in a relative amount of about 0.2 (Table 2) .
Hence the plasminf-a2-macroglobulin complex (CP) mainly contained Lys/Met/Val-plasmin.
Concluding remarks
Different molecular forms of plasminogen and different molecular forms of plasmin complexed to a1-plasmin inhibitor and a2-macroglobulin were identified in urokinase-activated plasma and clotted plasma. Plasminogen derivative bands with the same mobilities in acid/urea/polyacrylamide-gel electrophoresis appeared when plasma or clotted plasma was activated by high-fibrin-affinity-plasminogen activator (human melanoma cell activator, pig tissue activator) or by the low-fibrinaffinity-plasminogen activator urokinase (Thorsen et al., 1984) . It was therefore assumed that they had the same identities.
